Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AMGN said late Friday that denosumab significantly increased lumbar spine bone mineral density (BMD) vs. placebo at
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury